AZA Combined With NAC for PIT After HSCT

Launched by THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY · Nov 8, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients who have low platelet counts (a condition called thrombocytopenia) that does not respond well to standard therapies after receiving a stem cell transplant. The researchers want to see if combining two medications, Azacitidine and N-Acetyl-L-cysteine (NAC), can help improve platelet counts in these patients. Azacitidine is known to help with blood disorders, and NAC is an antioxidant that may help with the underlying issues related to low platelet counts.

To participate in this trial, patients must be between 65 and 74 years old and have a platelet count of 30 or below 30 billion cells per liter at least 60 days after their stem cell transplant. They should also have well-recovered white blood cells and hemoglobin levels, and a successful connection to the donor's cells. However, patients with active infections, certain severe complications from the transplant, or other serious health issues may not be eligible. Participants will receive the new treatment and will be monitored closely by the research team to see how well it works and if it is safe. This trial is not yet recruiting, so interested individuals will need to wait for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Platelet count ≤ 30 × 10\^9/L persistently at day 60 post-HSCT or later;
• • Neutrophil and hemoglobin were well recovered;
• • Full donor chimerism was achieved;
• Exclusion Criteria:
• • Patients with malignancy relapse;
• • Active infections;
• • Grade Ⅲ-Ⅳ acute graft-versus-host disease or severe chronic graft-versus-host disease according to National Institute of Health criteria;
• • Severe organ damage;
• • Thrombosis requiring treatment;